Press release
Rhinovirus Infection Therapeutics – Clinical Pipeline Development Analysis
Rhinovirus is a small, non-enveloped, icosahedral virus having size of around 27 nm diameter. It contains one positive-strand RNA and belongs to Picornavirus family. Discovered in 1956, rhinovirus has over 100 antigenically distinct serotypes such as RhV A, RhV B groups, and RhV A2 and RhV C subclasses, based on their sequence similarity and cell entry receptors. Human rhinovirus is a positive-sense RNA virus of 7.2 kb single strand, having single open reading frame joined to a 5′ untranslated region and a short viral priming protein. HRV A, HRV B and HRV C, are subtypes of human rhinovirus species, responsible for human diseases such as respiratory tract infection.Approximately 200 different viruses 30%-50% of all cases are known to cause symptoms of the common cold. The symptoms of the rhinovirus infection depend on the pathology associated with it. The most common symptoms include runny nose, nasal congestion, fever, headache, cough, sneezing, sore throat, rhinorrhea, croup in infants, tracheitis, and malaise that may last for 1 - 2 weeks.
Explore Report at: www.psmarketresearch.com/market-analysis/rhinovirus-infection-therapeutics-pipeline-analysis
The rhinovirus infection therapeutics pipeline has more than 15 drugs. In pipeline analysis, drugs are analyzed on the basis of route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Preclinical stage.
Phase III
Phase III clinical trial known for the comparison of new treatments with the standard treatment in which the safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. In rhinovirus infection therapeutics, there is no drugs has entered into Phase III trial.
Phase II
Interferon beta-1a, a Phase II drug candidate of Astrazeneca plc was licensed from Synairgen plc for further development and treatment of rhinovirus infections that exacerbates asthma and chronic obstructive pulmonary disease. Phase II clinical trial is the second phase that answer safety, efficacy and dosing of the new intervention. It takes around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.
Phase I
Phase I clinical stage has no single drugs for rhinovirus infection. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.
Request for Table of Content at: www.psmarketresearch.com/market-analysis/rhinovirus-infection-therapeutics-pipeline-analysis/toc-sample
Pre-Clinical
Clinical development pipeline analysis provides description about the key companies developing rhinovirus infection drugs. Some of the key players actively involved in the research and development are Novartis AG, Bioorganic Research and Services, S.A., Atopix Therapeutics, Ltd., Meissa Vaccines, Inc., 3-V Biosciences, Inc., Astrazeneca plc and AIMM Therapeutics.
Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com
347, 5th Ave. #1402
New York City, NY - 10016
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rhinovirus Infection Therapeutics – Clinical Pipeline Development Analysis here
News-ID: 470942 • Views: …
More Releases from P&S Market Research-

Revenue Cycle Management Market Analysis, Size, Share, Growth and Forecast to 20 …
The worldwide revenue cycle management market is witnessing considerable growth due to increasing regulatory requirements for the usage of revenue cycle management, increase in recovery audits due to changing healthcare regulations and increasing government support for revenue cycle management. Moreover, process improvements in healthcare organizations, increasing prevalence of chronic diseases and growing geriatric population are resulting in increased demand of revenue cycle management. Increasing number of patients and growth in…
More Releases for Phase
Three-Phase Hybrid Inverter Market Efficient and Reliable Power Conversion Solut …
Global Three-Phase Hybrid Inverter Market Overview:
The Three-Phase Hybrid Inverter market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Three-Phase Hybrid Inverter market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and globalization. This growth…
Clinical Trials by Phase (Phase I, Phase II, Phase III, Phase IV) Market Forecas …
A clinical trial is a research study, where a group of people is given a test or treatment. Clinical trials study the safety and efficacy of tests and treatments. If the test or treatment is safe and meets regulatory requirements, then it is approved as a standard of care.
Download Sample Copy at https://www.theinsightpartners.com/sample/TIPRE00006203/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
IQVIA
Parexel International Corporation
Charles River Laboratories
ICON plc
SGS SA
Chiltern International Ltd
Syneos Health
PRA Health Sciences
Wuxi AppTec Inc
Pharmaceutical Product Development,…
Digital Phase Shifters Market
Digital Phase Shifters Market A recently identified vacuum in the literature about the creation of digital phase shifters for modern communication systems is attempted to be filled in the book Design of Digital Phase Shifters for Multipurpose Communication Systems. By significantly reducing RF power consumption and improving noise immunity, directed beams enhance the development of new-generation mobile communication systems. In this regard, digital phase shifters in particular, which are part…
COVID-19 - Pipeline Analysis 2020 for Global Market | Emphasis on Products cover …
COVID-19 (also known as Anderson COVID-19)?is a viral disease caused by RNA virus, SARS-CoV-2 or commonly known as corona virus. These viruses can cause respiratory, enteric, hepatic, and neurologic diseases. At the end of 2019, a new coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China. It rapidly spread, resulting in an epidemic throughout China, followed by an increasing number of cases in other…
Power Metering Market Information by type (smart, digital, analog), by phase (si …
Power Metering Market Information by type (smart, digital, analog), by phase (single phase, three phase) by application (residential, commercial and industrial) and Region - Forecast to 2022
The report for Global Power Metering Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and…
HIV Vaccines Market Perceive Aggrandized Growth at a CAGR of 11.48% Till 2023 | …
HIV Vaccines Market Report Added on MarketResearchFuture.com with Overall Analysis. Key developments and Strategies Cover in this Report. The Market for Expected to Grow Globally Over the CAGR of 5 % During the Period 2018 to 2027 from USD 2,702.3 Billion in 2027.
HIV Vaccines Market - Segmentation
The global HIV vaccines market has been segmented on the basis of basis of antibiotics, type, and lastly, region.
Antibiotics have been segmented into dicloxacillin,…